Clinical Trial Search

Primary: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28) — 4.40; 4.03; 4.57; 4.48 units on a scale

Primary: Alteration of Microbiota, Alteration of T Cell Function/Activation — 4; 10; 2; 0 participants

Primary: Left Ventricular Mass Indexed to BSA, g/m^2 — 43.8; 42.2 g/m^2

Primary: 12 Month Change in 7-Joint Ultrasound (US) Inflammatory Score — 11.4 units on a scale — p=<0.01

Primary: Disease Activity — 3.38; 3.62 score on a scale

Primary: Percentage of Participants Achieving DAS28 Low Disease Activity at Week 12 — 21.2; 33.0 percentage of participants — p=0.055

Primary: RADAI Disease Activity Score — -0.4; 0.1 units on a scale — p=0.04

Primary: Percentage of CD27+ Switched Memory B Cells at Week 12 — 13.2; 13.8 Percentage of B Cells — p=0.3

Primary: Mean 48-week Change in DAS28 — -2.12; -2.29 units on a scale

Primary: Percentage of Participants Achieving American College of Rheumatology Score 20 Percent (ACR20) Response — 63.46; 76.15 Percentage of participants

Primary: Clinical Disease Activity Index (CDAI) Remission (≤2.8) at Both Week 20 and Week 24 — 18.8; 6.1 percentage of subjects

Primary: Number of Participants With a Diagnosis of Rheumatoid Arthritis (RA) by American Rheumatism Association (ARA) Criteria and/or Discontinued Due to Lack of Efficacy — 12…

Primary: Metabolic Syndrome Severity Z-score (MSSc) — -1.89; -1.82; -3.23; -3.49 Z-score (unitless) — p=<0.05

Primary: Osteoclast Differentiation Ex-vivo — 8; 12; 11; 5 OC/mm2

Primary: IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells of RA Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA. — 0.700; 1.330; 0.777…

Primary: Change in Diffusion Capacity for Carbon Monoxide (DLco) From Baseline to 48 Weeks — 4; 2; 1 participants

Primary: Percentage of Participants Achieving DAS28 Remission. — 6; 6 Participants — p=0.530

Primary: Number of Subjects With Lipids Checked (Available Now Through National Laboratory Chain) or That Reported Having Their Lipids Checked by Their 1-week or 3-month Visit…

Primary: Proportion of Patients Who Met the ACR20 Responder Index Criteria — 28.57; 35.06; 37.75; 38.57 Proportion of Patients — p=<0.001

Primary: Change in VO2 Max, Maximum Oxygen Uptake in ml/Min/kg is the Standard Index of Cardio-respiratory Fitness — 3.82; -0.44 ml/min/kg — p=0.002

Primary: CDAI Score — 36.06 score on a scale

Primary: DAS28-ESR — 3.75; 3.72; 3.59; 3.69 units on a scale — p=0.82

Primary: Normal Limits of TUVjoint in Healthy Subjects

Primary: Percentage of Adverse Events (AEs) — 55.0; 70.0; 57.9 Percentage of participant with AEs

Primary: Change From Baseline in Target Engagement Biomarkers- Soluble Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) Complexed to GSK3196165 — 0.972; 13.799; 0.960…

Primary: Change From Baseline on the Disease Activity Score Modified to Include the 28 Diarthrodial Joint Count-High-Sensitivity C-Reactive Protein (DAS28-hsCRP) — -0.99; -1.88…

Primary: Percentage of Participants With Categorized Laboratory Data Available at Baseline — 98.6; 49.2; 63.5; 7.3 percentage of participants

Primary: Number and Percent of Participants With Reduction of Immunity to Collagen Type-II After APLA-12 Treatment. — 9; 4 Participants — p=0.5179

Primary: Number of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 12 — 106; 59 participants — p=<0.001

Primary: Change From Baseline to Week 12 in Disease Activity Score (DAS) 28 (C-reactive Protein [CRP]) — -2.51; -2.65 score on a scale — p=0.022